medigraphic.com
ISSN 1561-302X (Print)

2012, Number 2

<< Back Next >>

Rev cubana med 2012; 51 (2)

Mortality and body mass index in patients with cardiac insufficiency

Chao PC, Roselló AY, Pernas GA, Valdés EY

Language: Spanish
References: 18
Page: 138-145
PDF size: 72.05 Kb.


ABSTRACT

Introduction: obesity is a risk factor to develop a heart failure, paradoxically, there has been less mortality in obese patients presenting with this affection. Objective: to analyze the relation between the body mss index (BMI) and the yearly mortality in patients seen in consultation of heart failure protocol. Methods: authors studied 70 patients followed for 1 year, who were classified according to its body mass index (BMI) in 4 groups: low (BMI <18,5), normal (BMI from 18,5 to 24,9), excess weight (BMI from 25 to 29,9) and obese (= 30). The BMI was related to mortality; the tests Chi2 and t Students were used to find the statistic significance, estimating the relative risk with a 95% CI.
Results: the risk of dye at 1 year was minor for obese patients regarding the cases with low weight and those with a normal weight, RR = 7,00 CI = (1,02-48,65) and CI 3,5 = (1,01-12,38), respectively. Other variables like the ejection fraction and the functional class not influenced on mortality, in all cases the p was greater than 0,05.
Conclusions: A body mass index great is a protection factor for mortality at 1 year of follow-up.


REFERENCES

  1. Roger V, Go A, Lloyd-Jones D, Adams R, Brown M, Carnethon R, et al. Heart Disease and Stroke Statistics—2011 Update: A Report From the American Heart Association. Circulation. 2011;123:e18-e209.

  2. Morales-Salinas A. Paradoja de la obesidad o susceptibilidad del bajo peso. Rev Esp Cardiol. 2008;61:653.

  3. Artham SM, Ventura HO. Insuficiencia cardiaca y la "paradoja de la obesidad": la historia continúa. Rev Esp Cardiol. 2007;60:1113-7.

  4. Fonarow GC, Srikanthan P, Costanzo MR, ADHERE Scientific Advisory Committee and Investigators. An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108.927 patients in the Acute Decompensated Heart Failure National Registry. Am Heart J. 2007;153:74-81.

  5. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol. 2004;43:1439-44.

  6. Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, Zhou Q, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med. 2007;120:863-70.

  7. Fonarow GC. The relationship between body mass index and mortality in patients hospitalized with acute decompensated heart failure. Am Heart J. 2007;15:e21.

  8. Lavie CJ, Mehra MR, Milani RV. Obesity and heart failure prognosis: paradox or reverse epidemiology? Eur Heart J. 2005;26:5-7.

  9. Steinberg BA, Cannon CP, Hernandez AF, Pan W, Peterson ED, Fonarow GC. Medical therapies and invasive treatments for coronary artery disease by body mass: the "obesity paradox" [cartas al editor]. Rev Esp Cardiol. 2008;61(6):653-5.

  10. Davos CH, Doehner W, Rauchhaus M, Cicoira M, Francis DP, Coats AJ, et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail. 2003;9:29-35.

  11. Habbu A, Lakkis NM, Dokainish H. The obesity paradox: fact or fiction? Am J Cardiol. 2006;98:944-8.

  12. Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med. 2005;165:55-61.

  13. Hu G, Jousilahti P, Antikainen R, Katzmarzyk P, Tuomilehto J. Joint Effects of Physical Activity, Body Mass Index, Waist Circumference, and Waist-to-Hip Ratio on the Risk of Heart Failure. Circulation. 2010;121:237-44.

  14. Rathore S, Curtis J, Wang Y, Bristol M, Krumholz H. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871-8.

  15. Cicoira M, Maggioni AP, Latini R, Barlera S, Carretta E, Janosi A, et al. Body mass index, prognosis and mode of death in chronic heart failure: Results from the Valsartan Heart Failure Trial. Eur J Heart Fail. 2007;9:397-402.

  16. Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LA, Skali H, et al; CHARM Investigators. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007;116:627-36.

  17. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow G, Norris CM, McAlister FA. Body mass index and mortality in heart failure: A meta-analysis. Am Heart J. 2008;156:13-22.

  18. Schrier R, Abraham WT. Hormones and hemodynamics in heart failure. N Eng J Med. 1999; 341:577-85.




2020     |     www.medigraphic.com